XRTX and ANUA Related Headlines
Go Back- XORTX regains Nasdaq compliance after reverse stock split
- XORTX Meets Nasdaq Continued Listing Requirements
- XORTX completes $3 million acquisition of kidney disease asset VB4-P5
- XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset
- XORTX Therapeutics sets April 6 date for 1-for-5 share consolidation
- XORTX Confirms Effective Date of Share Consolidation
- XORTX Announces Results of Annual and Special Meeting of Shareholders
- XORTX delays share consolidation to April 6 from March 27
- XORTX Announces Change of Effective Date of Share Consolidation
- XORTX completes 1-for-5 share consolidation to meet NASDAQ requirements
- XORTX Announces Share Consolidation
- XORTX shareholders approve share consolidation to meet NASDAQ rules
- XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General Meeting
- XORTX Announces Substitute Director Nominees for its Upcoming Annual and Special Meeting of Shareholders
- XORTX receives proxy firm backing for share consolidation vote
- XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote “For” the Share Consolidation
- XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders
- XORTX extends deadline to complete Vectus acquisition to March
- XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
- XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update
- XORTX closes $1.1 million registered direct offering
- XORTX Announces Closing of US$1.1 Million Registered Direct Offering
- XORTX prices $1.1 million registered direct offering at $0.63 per share
- XORTX Announces Pricing of US$1.1 Million Registered Direct Offering
- XORTX receives 180-day extension from NASDAQ for bid price compliance
- XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency
- XORTX receives Nasdaq notice for minimum bid price deficiency
- XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
- XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
- Join XORTX for an Exclusive Live Investor Webinar and Q&A Session on September 10
- XORTX Initiates IND Preparation for XORLO™ in Gout Program
- XORTX Provides Corporate Update and Planned Activities for 2025 / 2026
- XORTX raises $114,500 through private placement of common share units
- XORTX Announces USD $114,500 Private Placement
XRTX and ANUA Related Press Releases
Go Back- XORTX Meets Nasdaq Continued Listing Requirements
- XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset
- XORTX Confirms Effective Date of Share Consolidation
- XORTX Announces Results of Annual and Special Meeting of Shareholders
- XORTX Announces Change of Effective Date of Share Consolidation
- XORTX Announces Share Consolidation
- XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General Meeting
- XORTX Announces Substitute Director Nominees for its Upcoming Annual and Special Meeting of Shareholders
- XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote “For” the Share Consolidation
- XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders
- XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
- XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update
- XORTX Announces Closing of US$1.1 Million Registered Direct Offering
- XORTX Announces Pricing of US$1.1 Million Registered Direct Offering
- XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency
- XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
- XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
- Join XORTX for an Exclusive Live Investor Webinar and Q&A Session on September 10
- XORTX Initiates IND Preparation for XORLO™ in Gout Program
- XORTX Provides Corporate Update and Planned Activities for 2025 / 2026
- XORTX Announces USD $114,500 Private Placement
